Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation
International Journal of Neonatal Screening · 17.01.2024 · 10 (1) · 6
DOI: 10.3390/ijns10010006 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 17.01.2024. Verfasst von Fiona Lynch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Ethics Research Group, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Victorian State Government, Australian Government.
Abstract (Originalsprache)
Recent dramatic reductions in the timeframe in which genomic sequencing can deliver results means its application in time-sensitive screening programs such as newborn screening (NBS) is becoming a reality. As genomic NBS (gNBS) programs are developed around the world, there is an increasing need to address the ethical and social issues that such initiatives raise. This study therefore aimed to explore the Australian public’s perspectives and values regarding key gNBS characteristics and preferences for service delivery. We recruited English-speaking members of the Australian public over 18 years of age via social media; 75 people aged 23–72 participated in 1 of 15 focus groups. Participants were generally supportive of introducing genomic sequencing into newborn screening, with several stating that the adoption of such revolutionary and beneficial technology was a moral obligation. Participants consistently highlighted receiving an early diagnosis as the leading benefit, which was frequently linked to the potential for early treatment and intervention, or access to other forms of assistance, such as peer support. Informing parents about the test during pregnancy was considered important. This study provides insights into the Australian public’s views and preferences to inform the delivery of a gNBS program in the Australian context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedical Ethics Research Group, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
- Melbourne Law School, The University of Melbourne, Melbourne, VIC 3052, Australia.
- Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia.
- Australian Genomics, Melbourne, VIC 3052, Australia.
- Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia.
- Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
ORCID-Profile: Fiona Lynch, Alison D Archibald, Zornitza Stark, Danya F Vears
Förderung
- Wellcome Trust
- Victorian State Government
- Australian Government
Zitieren
APA
Lynch, F., Best, S., Gaff, C., Downie, L., Archibald, A. D., Gyngell, C., Goranitis, I., Peters, R., Savulescu, J., Lunke, S., Stark, Z., & Vears, D. F. (2024). Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation. International Journal of Neonatal Screening, 10(1), 6. https://doi.org/10.3390/ijns10010006
Vancouver
Lynch F, Best S, Gaff C, Downie L, Archibald AD, Gyngell C, et al. Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation. International Journal of Neonatal Screening. 2024;10(1):6. doi:10.3390/ijns10010006
BibTeX
@article{Lynch2024,
author = {Lynch, Fiona and Best, Stephanie and Gaff, Clara and Downie, Lilian and Archibald, Alison D and Gyngell, Christopher and Goranitis, Ilias and Peters, Riccarda and Savulescu, Julian and Lunke, Sebastian and Stark, Zornitza and Vears, Danya F},
title = {Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation},
journal = {International Journal of Neonatal Screening},
year = {2024},
volume = {10},
number = {1},
pages = {6},
doi = {10.3390/ijns10010006}
}
EUVIMED